In the throes of litigation synonymous with one of our time's most devastating public health crises, Baltimore City has clinched a settlement with pharmaceutical giant Johnson & Johnson just as the civil trial was to unfurl its legal narratives against the company. As it currently stands, the precise details of this agreement remain opaque, shielded from public scrutiny.
A city spokesperson verified the arrangement, stating, per FOX Baltimore report, "I can confirm the city settled with Johnson & Johnson. The City cannot at this time discuss any of the specific terms of the settlement." This recent accord is a fragment of a broader legal effort by Baltimore against various drug manufacturers and distributors, holding them accountable for a crisis that has ensnared the city in a web of addiction and despair.
Baltimore's litigation strategy has yielded previous settlements, including agreements with Walgreens Pharmacy and Teva Pharmaceuticals. As WMAR-2 News reports, Teva alone has been directed to pay Baltimore $80 million, with a prompt $35 million by the end of the year and the balance by July 1, 2025. Meanwhile, the specifics of the Walgreens settlement linger in confidentiality, with an October reveal scheduled.
The city's anti-opioid crusade continues as funds from these settlements have been earmarked for vital community initiatives. Among them, is a $5 million commitment to championing the "988" suicide/crisis hotline, with additional millions funneled into the Penn North Recovery Center and BMore Power. This financial gesture is instilled with the hope of rectifying, if only partly, the harrow that "Big Pharma" has wrought upon the city's residents through what the city labeled as "fraudulent and reckless marketing of opioids," as reported by WMAR-2 News.
